SCHEMBL6093439

SCHEMBL6093439

Cc1cc(C)c(-c2cccn3c2cc2nc(C)cc(NCCN)c23)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 1/20 0.40
CRHR1 P34998 4/20 0.34
CYP2C19 P33261 1/20 0.33
NQO2 P16083 3/20 0.32
NCF1 P14598 2/20 0.32
PRKD2 Q9BZL6 2/20 0.31
IKBKB O14920 2/20 0.31
CHUK O15111 2/20 0.31
ERN1 O75460 1/20 0.31
RPS6KA4 O75676 1/20 0.31
PRKD3 O94806 1/20 0.31
CDK1 P06493 1/20 0.31
KIT P10721 1/20 0.31
CDK11B P21127 1/20 0.31
CDK2 P24941 1/20 0.31
TYK2 P29597 1/20 0.31
CSNK1D P48730 1/20 0.31
CDK7 P50613 1/20 0.31
CDK9 P50750 1/20 0.31
LIMK1 P53667 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093905 0.83 NPY1R (0.35) NPY1RCRHR1PRKD2IKBKBCHUK
SCHEMBL6092887 0.78 PTPN1 (0.37) CRHR1
SCHEMBL6095943 0.78 LMNA (0.36) CRHR1
SCHEMBL6095184 0.76 USP2 (0.40) NPY1R
SCHEMBL6094492 0.74 CRHR1 (0.56) NPY1RCRHR1
SCHEMBL6094785 0.74 KMT2A (0.39) CYP2C19
SCHEMBL6092967 0.71 PTPN1 (0.35)
SCHEMBL6093564 0.71 CDK5 (0.32)
SCHEMBL6094470 0.69 CRHR1 (0.33) CRHR1
SCHEMBL6095564 0.68 NPY1R (0.42) NPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed
US-6506762-B1 Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating NEUROGEN CORPORATION 2003-01-14 US disclosed
EP-1224187-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2002-07-24 EP disclosed
WO-2001023389-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R NPY1R 1/4885CRHR1 16/4885CYP2C19 1614/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R NPY1R 1/4885CRHR1 14/4885CYP2C19 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.